Literature DB >> 24592496

Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups a systematic review.

Amy Earley, Rebecca Persson, Ann C Garlitski, Ethan M Balk, Katrin Uhlig.   

Abstract

BACKGROUND: Previous systematic reviews of implantable cardioverter defibrillators (ICDs) used for primary prevention of sudden cardiac death (SCD) concluded that ICDs are less effective in women and the elderly.
PURPOSE: To examine ICD effectiveness for primary prevention of SCD across subgroups by sex, age, New York Heart Association class, left ventricular ejection fraction, heart failure, left bundle branch block, QRS interval, time since myocardial infarction, blood urea nitrogen level, and diabetes. DATA SOURCES: MEDLINE and the Cochrane Central Register of Controlled Trials through 3 September 2013 with no language restriction. STUDY SELECTION: Researchers screened articles for studies comparing ICD versus no ICD for primary prevention. DATA EXTRACTION: Data were extracted about study design, patients, interventions, mortality and SCD outcomes, subgroup characteristics, and subgroup effects. Quality of subgroup analyses was determined by consensus. Relative odds ratios comparing subgroup effects were calculated, and random-effects model meta-analyses were conducted on these ratios. DATA SYNTHESIS: Meta-analysis of 14 studies showed a decrease in deaths and SCDs due to ICD treatment. Ten studies provided subgroup analyses. Nine studies compared ICD versus no ICD, whereas one compared cardiac resynchronization therapy plus a defibrillator versus no ICD. Within-study interaction tests and across-study meta-analyses yielded weak evidence that did not show differences for all-cause mortality in subgroups by sex, age, and QRS interval. The evidence was indeterminate for other evaluated subgroups because of a paucity of data. LIMITATION: Many subgroup analyses were underpowered, which may have resulted in false-negative findings.
CONCLUSION: Weak evidence fails to show differences for all-cause mortality in subgroups of sex, age, and QRS interval. Evidence is indeterminate for all-cause mortality in the other subgroups and for SCD. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Entities:  

Mesh:

Year:  2014        PMID: 24592496     DOI: 10.7326/M13-1787

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  7 in total

1.  Predicting cardiac events using ventricular dyssynchrony in patients who received implantable cardioverter defibrillators: Are more treatment options required?

Authors:  Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2015-11-24       Impact factor: 5.952

Review 2.  Contemporary Management of Heart Failure in the Elderly.

Authors:  Joanna Osmanska; Pardeep S Jhund
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

Review 3.  Systolic heart failure: knowledge gaps, misconceptions, and future directions.

Authors:  Rohan Samson; Rohit Ramachandran; Thierry H Le Jemtel
Journal:  Ochsner J       Date:  2014

Review 4.  Long-term efficacy of implantable cardiac resynchronization therapy plus defibrillator for primary prevention of sudden cardiac death in patients with mild heart failure: an updated meta-analysis.

Authors:  Wei-Ping Sun; Chun-Lei Li; Jin-Cheng Guo; Li-Xin Zhang; Ran Liu; Hai-Bin Zhang; Ling Zhang
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

Review 5.  Adverse events following implantable cardioverter defibrillator implantation: a systematic review.

Authors:  Rebecca Persson; Amy Earley; Ann C Garlitski; Ethan M Balk; Katrin Uhlig
Journal:  J Interv Card Electrophysiol       Date:  2014-06-20       Impact factor: 1.900

6.  Age and sex differences in long-term outcomes following implantable cardioverter-defibrillator placement in contemporary clinical practice: findings from the Cardiovascular Research Network.

Authors:  Frederick A Masoudi; Alan S Go; David J Magid; Andrea E Cassidy-Bushrow; Jerry H Gurwitz; Taylor I Liu; Kristi Reynolds; David H Smith; Liza M Reifler; Karen A Glenn; Frances Fiocchi; Robert Goldberg; Nigel Gupta; Pamela N Peterson; Claudio Schuger; Humberto Vidaillet; Stephen C Hammill; Robert T Greenlee
Journal:  J Am Heart Assoc       Date:  2015-06-02       Impact factor: 5.501

Review 7.  Current Therapeutic Options for Heart Failure in Elderly Patients.

Authors:  F Guerra; M Brambatti; M V Matassini; A Capucci
Journal:  Biomed Res Int       Date:  2017-11-15       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.